We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

“Softer” Mass Spec Techniques Gain Advantage in Biomarker Discovery

By LabMedica International staff writers
Posted on 29 Mar 2015
Two mass spectrometry (MS) technologies, MALDI and DESI, are increasing in applications as their effectiveness is established, according to Kalorama Information (New York, NY, USA) in its report “Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies).”

MS is the most powerful tool in proteomic biomarker discovery and validation. Through its traditional techniques MS has struggled to elucidate tissue molecular distribution related to disease state. In recent years, MS imaging, including MALDI and DESI imaging, has seen significant application in proteomic biomarker discovery with its distinct advantages in preservation of spatial proteomic data and potential to improve assay reproducibility.

In MALDI and DESI, nondestructive techniques are utilized with soft ionization sources to desorb and ionize surface molecules for MS analysis. According to Kalorama, one of the key strengths of MALDI and DESI is that they avoid traditional tissue sample preparation, a tedious front-end process that presents a significant bottleneck in proteomics where differential analysis is used to compare protein expression and abundance between samples. Proteolytic digestion and other sample preparation procedures remove significant analytical context value related to protein spatial distribution and concentration.

Kalorama believes that a number of studies have cemented the reputation of these MS technologies. Researchers have noted the novelty of MALDI imaging of tissue (introduced in 1997) to discover proteins otherwise difficult to separate by electrophoresis or hidden in shotgun proteomic processes that are biased towards higher-mass proteins. Recent studies have used MALDI imaging to discover several biomarkers associated with gastric cancer survival prognosis, forms of ovarian cancer, and to develop a novel grading system for papillary non-invasive bladder cancer.

Kalorama’s report contains breakouts of the market by type of technology used and application. It profiles companies and surveys partnerships and deals related to proteomics.

Related Links:

Kalorama Information
Proteomics Markets for Research and IVD Applications, report


New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit

Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more